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Abstract: Introduction: Enzyme-linked immunosorbent assay (ELISA) is a plate-
based assay intended for measuring proteins and antibodies. (1) The ELISA method is 
tedious and a lengthy process. (2) HemosIL AcuStar VWF:CB is a fully automated 
method. Several publications have described a comparison between an ELISA method 
and an automated method. A comparison was performed to evaluate the automated 
method. Method: A comparison between TECHNOZYM ® vWF:CBA ELISA and 
HemosIL AcuStar VWF:CB was performed. A total of 44 samples was included in the 
comparison which included congenital and acquired vWD. A reference interval was 
established; 50 healthy donors were collected from New Zealand Blood Service and 
from the laboratory and run on the and HemosIL AcuStar VWF:CB. Results: The 
HemosIL AcuStar is statistically analysed by Pearson’s Correlation coefficient (r2 ) and 
it showed a strong linear relationship (r=0.9795) with a negative bias of -14.6. The p-
value was 0.0722 (>0.05) which is not statistically significant showing a strong 
evidence that even with a small sample size, the Hemosil AcuStar is a suitable 
replacement for Technozyme ELISA method. Conclusions: The statistical analysis 
demonstrated a good correlation between Acustar VWF:CB and ELISA assays for 
normal and VWD patients. HemosIL AcuStar VWF:CB is a potential alternative to a 
ELISA method for measuring CBA levels.  
Keywords: Automation, Chemiluminescent assay, Collagen Binding Activity, 
ELISA, Von Willebrand Disease  
 
Introduction:  
The von Willebrand Factor (vWF) is a large glycoprotein, necessary for primary 
and secondary haemostasis. vWF has many functions; It carriers and protects Factor 
VIII from early proteolytic breakdown. It is a facilitator for platelet aggregation by 
fastening to GP Ib and GP lIb/IIIa. It also facilitates linkage between platelets and the 
sub-endothelium. Collagen binding activity (CBA) measures the ability for vWF to 
bind to platelet glycoprotein Ib (GPIb) and fuel platelet plug development. (3)  
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Von Willebrand disease (vWD) is the most common inherited bleeding disorder. 
VWD is categorised as either Type 1, Type 2 or Type 3. Type 1 and type 3 are 
quantitative defects. Type 2 is a qualitative defect that is additionally classified into 4 
sub-groups;  
• VWD type 2A is a qualitative variant with weakened VWF‐dependent platelet 
adhesion and a deficiency of high–molecular‐weight multimers.  
• VWD type 2N has diminished binding affinity for factor F VIII.  
• VWD type 2B has an amplified affinity for platelet GPIb i.e. “gain of function”. 
•  VWD type 2M with reduced platelet adhesion. 
The appropriate classification of VWD is critical for therapeutic controlling of 
patients. (4)  
Enzyme-linked immunosorbent assay (ELISA) is a plate-based technique is used 
for measuring proteins and antibodies. (1) The ELISA method is monotonous and 
lengthy practice. (2) HemosIL AcuStar VWF:CB is a fully automated method that 
could potentially replace the ELISA method. Several publications have described a 
comparison between an ELISA method versus and an automated method. Notably, “A 
comparative evaluation of a new fully automated assay for von Willebrand factor 
collagen binding activity to an established method” by F Stufano, L Baronciani, D 
Mane-Padros, G Cozzi S Faraudo, F Peyvandi reported good correlation between the 
methods (4) . However a limitation to this comparison was the addition of acquired von 
Willebrand samples.  
Methods and Materials:  
The reference method being TECHNOZYM ® vWF:CBA and the comparative 
method being HemosIL AcuStar VWF:CB ;  
TECHNOZYM ® vWF:CBA is a sandwich ELISA assay. The ELISA test strips 
are shielded with human Type 3 collagen. VWF in the sample binds to the collagen. A 
peroxidase conjugated antibodies are joint to the anti-human vWF multimers. An 
enzymatic reaction takes place between hydrogen peroxide and substrate which gets 
finalized by sulphuric acid. The colour intensity is calculated photometrically. (5)  
HemosIL AcuStar VWF: CB is a chemiluminescent is a 2-step immunoassay. 
Sample is mixed with assay buffer along with the magnetic particles that are covered 
with type 3 “collagen-tripe-helical peptide”. VWF binds to the magnetic particles based 
on its collagen binding activity. Magnetic separation and washing, the particles are 
incubated with an isoluminol- labelled anti vWF polyclonal antibody. A final magnetic 
separation washing and triggers are added and a chemiluminescent reaction is 
measured. (6)  
All 40 samples were venous collects drawn in 3.2% sodium citrate tubes. The 
remaining 4 samples were external quality control. Platelet‐poor plasma was prepared 
by double centrifugation at 4000 rpm for 10 min at room temperature. The samples 
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were stored at −20 °C and thawed for 5 minutes in a warm water bath at 37 °C prior to 
running. Samples were double spun and frozen within 4 hours of collection. Plasma 
that was haemolysed, icteric or lipaemic were not included in the evaluation.  
The samples had a request for von Willebrand screen. Ethical approval was not 
required. A wide range of CBA levels were included. To help with the search of 
samples for the validation, the following clinical details were used; 
• Low levels of von Willebrand  
• Blood O group 
• Acquired von Willebrand secondary to Waldenström macroglobulinemia (WM)  
• Von Willebrand Disease 
• Severe acquired von Willebrand secondary to Monoclonal gammopathy of 
undetermined significance (MGUS)  
The Royal College of Pathologists of Australasia Quality Assurance 
Programs (RCPAQAP) was also run as part of the validation process; RCPA-21-01, 
RCPA-21-02, RCPA-21-03 & RCPA-21-02. Calibration, quality control and patient 
samples were run as per manufactures instructions.  
A reference interval was established; 50 healthy donors were collected from New 
Zealand Blood Service and from around the laboratory and were run on the 
HemosIL AcuStar VWF:CB. A reference interval was derived from the mean and 
standard deviation (SD) i.e. + and – 2 SD from the mean. The medium, upper quartiles 
and lower quartiles were included.  
Statistical analysis  
The statistical analysis was performed using Microsoft excel, for the Pearson’s 
correlation coefficient between the TECHNOZYM ® vWF:CBA and 
HemosIL AcuStar VWF: CB. The Bland Altman plot was used to calculate the 95% 
limit of agreement. P-value was calculated from Microsoft excel. Shapiro-Wilk test 
was used to establish normality for the difference between the measurement methods. 
The Shapiro-Wilk test was calculated using statistics kingdom calculator. The 95% 
confidence interval were calculated by Social Science statistics calculator.  







1 42 67 Low von Willebrand levels  
2 55 74 Blood group O  
3 39 68 Low von Willebrand levels 
4 83 130 Normal 
5 37 53 Suggest repeating  
6 49 68 Suggest repeating 
7 75 107 Normal 
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8 35 47 Acquired von Willebrand disease 
secondary to hypothyroidism  
9 22 28 Type 2M von Willebrand disease 
10 3 3 Severe acquired von Willebrand disease 
secondary to MGUS 
11 37 65 Type 2M von Willebrand disease  
12 47 68 Low von Willebrand levels  
13 36 
 
45 RCPA result = 36 RCPA-21-01 Mild 
type 1 von 
Willebrand disease  
14 3 2 RCPA result= 3 RCPA-21-02 Mild 
type 2 A/B von 
Willebrand disease 
15 18 13 Acquired Moderate Von Willebrand 
disease secondary to MGUS 
16 36 43 Acquired Von Willebrand disease 
secondary to WM 
17 29 44 Von Willebrand disease 
18 55 75 Normal  
19 41 61 Low Von Willebrand levels 
20 42 54 Low Von Willebrand levels 
21 59 79 Normal  
22 50 72 ? von Willebrand Disease 
23 57 74 ? von Willebrand Disease 
24 26 28 Type 2B von Willebrand Disease 
25 22 29 Type 2B von Willebrand Disease 
26 50 71 ? von Willebrand Disease 
27 89 112 Normal 
28 100 120 Normal 
29 10 11 Acquired Moderate Von Willebrand 
disease secondary to MGUS 
30 3 4 Severe acquired von Willebrand 
Disease secondary to MGUS 
31 39 59 Mild Type 2B von Willebrand Disease 
32 3 3 Severe acquired von Willebrand 
Disease secondary to MGUS 
33 80 95 Normal 
34 52 74 ? von Willebrand Disease 
35 90 111 Normal 
36 80 109 Normal 
37 85 112 Normal 
38 2 3 Type 3 von Willebrand Disease 
39 135 150 Normal 
40 20 25 Type 2B von Willebrand Disease 
41  3 3 RCPA result= 5 RCPA-21-03 Type 2 
A/B von Willebrand 
disease 
42 55 74 RCPA result=80 RCPA-21-04 Normal  
43 20 21 Type 1 von Willebrand Disease 
44 1 1 Type 3 von Willebrand Disease  
Mean  44 58  
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Numerical data for the Bland-Altman plot 
Bias  -14.6 
Lower limit -36.6 
Upper limit 7.5 
Table 3 
Waikato normal reference interval 
Sample ID HemosIL ABO DOB Gender  
1 128 A 07/08/1973 F 
2 160 B 25/10/1993 M 
3 195 A 03/01/1996 F 
4 192 O 25/09/1989 F 
5 105 O 04/04/2001 M 
























































Average of the CBA % between the CBA kits
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6 88 O 20/05/1985 F 
7 164 O 13/08/1985 F 
8 126 A 20/05/1968 F 
9 140 B 18/07/1954 F 
10 131 O 12/11/1970 F 
11 175 A 15/07/1950 M 
12 157 A 30/01/1978 F 
13 98 A 09/09/1967 F 
14 98 B 28/05/1952 F 
15 146 O 18/09/1997 F 
16 175 A 17/12/1971 F 
17 128 A 09/11/1955 M 
18 200 O 15/05/1969 M 
19 200 O 11/12/1968 M 
20 122 O 27/06/1991 M 
21 73 A 31/08/1990 M 
22 99 B 08/11/1999 F 
23 81 A 09/09/1958 M 
24 105 A 11/09/1987 M 
25 177 A 27/09/1984 M 
26 90 A 29/08/1969 M 
27 111 O 20/01/1984 M 
28 200 O 08/04/1970 F 
29 120 O 22/10/1955 F 
30 81 O 03/04/1995 M 
31 122 A 22/11/1967 F 
32 142 O 30/10/1968 F 
33 186 B 19/01/1982 F 
34 97 A 18/12/1982 F 
35 132 O 08/06/1960 F 
36 264 A 18/10/1984 F 
37 126 B 16/19/1983 M 
38 140 O 21/12/1963 F 
39 131 A 23/05/1978 F 
40 175 B 19/08/1960 M 
41 157 A 18/10/1984 M 
42 98 A 01/12/1974 M 
43 95 O 08/03/1986 M 
44 110 O 20/01/1964 M 
45 81 A 20/05/1969 F 
46 169 O 31/12/1955 F 
47 154 A 28/07/1993 F 
48 113 O 16/01/1962 M 
49 101 A 23/05/1978 F 
50 97 A 02/01/1994 F 
Mean  133    
SD  44    
Lower limit 60    
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Table 4 



























Mean =108% Mean=40% 
SD= 5.7 SD=1.8 
CV= 5.3% CV= 4.6% 
Discussion and conclusion 
The study compared results between HemosIL AcuStar VWF:CB assay and the 
TECHNOZYM ® vWF:CBA ELISA ELISA . The AcuStarVWF:CB assay is much 
quicker than the TECHNOZYM ® vWF:CBA ELISA method. The ELISA method had 
two 45-minute incubation periods along with two manual washing steps. Including 
reconstitution time, it takes approximately 3 hours to get a CBA result. This process 
requires bench space and relatively consistent pipetting technique in order to achieve 
coefficient variation (CV) of < 10 % for each sample as the wells are pipetted in 
duplicate. (5) In contrast, the AcuStarVWF:CB assay is fully automated, with a 
turnaround time of 33 minutes, this time doesn’t include the reconstitution of quality 
control which is another 30 minutes. The reagent can stay on board for up to 5 weeks. 
(6) Statistical analysis found an acceptable correlation between AcuStar VWF:CB and 
ELISA assay. In fact the Pearson’s correlation coefficient (r²) of 0.9595 was similar to 
a study “Comparison of an automated chemiluminescent assay to a manual ELISA 
assay for determination of von Willebrand Factor collagen binding activity on VWD 
"Science and Education" Scientific Journal / ISSN 2181-0842 November 2021 / Volume 2 Issue 11
www.openscience.uz 251
plasma patients previously diagnosed through molecular analysis of VWF” They 
reported an r value of 0.9571.  
It should be noted; due to the nature of the validation, only 44 samples were used. 
In contrast to the E. Jousselme, Y. Jourdy1, L. Rugeri, C. Négrier & C. Nougier study 
that used 49 samples. Another difference is that their study used a different ELISA kit; 
Stago-Asserachrom ® . The difference in CBA ELISA kits and number of samples did 
not overly effect the R-value as both were relatively the same. P value was calculated 
as 0.0722. Sample 1, 3, 5, 6, 11, 12, 19, 20 & 31 have a CBA result difference that the 
author believes is clinically significant. These differences in values have the potential 
to alter the diagnosis of a patient. Confirmation of the diagnosis for 9 samples proved 
challenging as sample 1, 3, 12, 19 & 20 have been diagnosed with “Diagnosis of Low 
von Willebrand Factor” and did not have molecular testing to help distinguish the 
diagnosis. The two CBA kits have different collagen source, which may influence the 
detection of some type 2 VWD as mentioned in the E. Jousselme, Y. Jourdy1, L. 
Rugeri, C. Négrier & C. Nougier study. Type III human placental collagen is the 
collagen used for ELISA whereas synthetic peptides for Acustar.  
Sample 5 had several repeat sample samples to confirm the CBA results. Each 
time the results remained low and it was referred to the laboratory haematologist. 
“Blood group is not known and testing is recommended as those with blood group O 
are known to have naturally lower levels of vWF. However, results mean that low vWF 
cannot be excluded (vWD is diagnosed when levels are < 35% which they are not in 
this case but there is increasing recognition that patients can have symptoms with levels 
between 35-50% as in this case). Repeat testing may be required on several occasions 
to capture those levels (and is recommended in this case) as vWF can also be increased 
in stress/post exercise etc. Regardless all results should be interpreted in the clinical 
context i.e. family and personal history of bleeding. If this is significant then 
haematology referral may be appropriate for further work up.” Unfortunately, no 
follow up from the GP was initiated leaving this sample with an unclear diagnosis. 
Sample 6 only had one round of testing leaving it impossible to interpret without follow 
up from the GP. Sample 11 had a confirmed diagnosis of Type 2M von Willebrand. 
This was confirmed with molecular studies at the time of diagnosis. Sample 6 only had 
the one result and a repeat sample to confirm the results wasn’t done. Sample 31 had 
molecular studies confirm a mild Type 2B von Willebrand disease.  
This study is unique from other studies as acquired von Willebrand syndrome 
(aVWS) patients were included. A total of 7 samples with known aVWS were added 
to the comparison. Other studies concentrate solely on congenital vWD, however the 
importance of diagnosing AVWS should not be dismissed. AVWS is a rare disorder 
that mimics hereditary VWD and can cause life-threatening bleeding. Mechanisms of 
reduced VWF activity in AVWS can be either immune or non-immune. Causes for 
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aVWS with the 7 samples were hypothyroidism, MGUS and WM. MGUS and WM 
have para-proteins that can effect testing. While the main mechanism of aVWS in 
hypothyroidism is the fall of VWF production, autoantibodies against VWF have been 
associated with autoimmune thyroiditis. (7) The author felt it was imperative to include 
aVWS patients as the varying mechanisms could affect the testing of the CBA levels. 
HemosIL compared well with the ELISA method and followed the same pattern as 
congenital vWD. HemosIL ran higher at >20 % while lower levels were identical.  
The RCPA material was run and found that there was excellent correlation with 
RCPA-21-02 Mild type 2 A/B von Willebrand disease. Interestingly, with RCPA-21-
01 Mild type 1 von Willebrand disease the Elisa method was identical to the RCPA 
peer result at 36 %. However, the HemosIL method ran higher at 45%. This is 
consistent with the results in table 1. RCPA-21-03 ran at 3 % for both methods and the 
RCPA peer mean was 5%. The RCPA-21-04 showed that the ELISA CBA result was 
55% and the HemosIL method as predicated then higher at 74%. Remarkably, the 
HemosIL method was closer to the RCPA peer mean of 80%. Both sets of RCPA 
results reflect that the HemosIL method runs higher than the ELISA method, results in 
the lower range don’t have this pattern.  
Scatter plot Figure 1, showed an excellent correlation between the ELISA and 
HemosIL method with an r value 0.9595. A Bland-Altman Plot was plotted, shown in 
Figure 2. A negative bias was also observed on the Bland-Altman plot of -14.6 which 
is almost three times as what has been cited in the Jousselme, Y. Jourdy1, L. Rugeri, 
C. Négrier & C. Nougier study. They reported a Bias of + 5.1 U/dL .The author believes 
the main reasons for the difference in bias is the number of sample numbers used in 
the study and the fact that different kits for ELISA’s were used. Although the bias was 
higher, the R-value for both studies was similar and the bias was corrected by the 
regression. With 95% confidence the population mean was calculated between -17.9 
and -11.3 based on the 44 samples. The line of equality is centred at 14.6. It is possible 
to say that the bias is not significant as the line of equality is between the calculated 
confidence intervals. The 95 percent 'limits of agreement' was calculated as the mean 
of the two values, minus and plus 1.96 standard deviations.  
It appears that the ELISA CBA method fits the clinical scenario more effectively 
than the HemosIL method under the reference interval of 50-150% which was of 
concern. The previously mentioned samples had a result difference that would affect 
the clinical interpretation i.e. low values to normal levels. This is of clinical reference 
and must be invested further. The AcuStarVWF:CB assay runs at a higher % then the 
ELISA assay. However, there was excellent correlation with CBA results that were < 
20 %. The overall increase in CBA levels with the HemosIL method was further 
explored with 50 normal samples. These normal sampled were used to establish the 
reference interval for the AcuStarVWF:CB assay. 
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CLSI guidelines states that the chief means to inaugurate reference interval is to 
collect 120 samples for investigation. CLSI also states that individual laboratories 
should concentrate more on verifying reference ranges. (8) The CBA was a previously 
established method, 50 samples were used for the reference interval. A mean of 133 % 
and a SD of 36 % was calculated from the normal donors. The medium of the reference 
interval data was slightly lower than the mean at 129%. The lower quartile was 
calculated at 98.85% and the upper quartile was calculated as 161%. The interquartile 
range was 62.15%. The reference interval was 60-205 %. The reference interval was 
derived from the mean and standard deviation (SD) i.e. + and – 2 SD from the mean. 
Using the Shapiro-Wilk Test the data was tested for normality. The skewness contour 
was hypothetically symmetrical (Pval=0.3). Normality of the data was accepted.  
Due to the overall higher percentage of CBA results on the Acustar, the decision 
was made to move the reference interval from to 70-150%. The reference interval 
change compensates for the higher level that the HemosIL runs at and corrects the 9 
samples that would have been missed otherwise. The manufacture’s precision is in 
accordance with CLSI document EP5-A3. (9) CLSI document EP15 was used for this 
study as the author wished to only verify the manufactures claims. (10) A sample was 
run 25 times over 5 days for abnormal and normal sample. This showed a CV of 5.3% 
for the normal sample and 4.6% for the abnormal sample. SD for the normal sample 
was 5.7 and the abnormal 1.8. This results correlated well with manufactures results.  
This study includes an investigation on the reference interval. Because the 
different ABO blood groups have varying CBA levels, it is important to acknowledge 
that out of the 50 donors 20 had a blood group O which has lower levels of VWFs 
levels then other ABO blood types. The rest of the donors would have naturally higher 
VWF levels. (10) This could increase the mean and therefore the overall reference 
intervals. The manufactures reference intervals for all blood groups was 50.5-181.2%. 
The manufactures used a total of 261 donors of which 140 donors were group. This is 
a significantly higher proportion of group O donors then the reference range that was 
verified. This could explain the lower reference range along with the increased number 
of donors. It does not state the age or gender of the 261 donors which also adds to the 
variety of the reference interval. There are many variables that can effect VWF levels, 
it’s prudent for each laboratory to set up their own reference interval. (6)  
Limitations  
This study is not without limitations; only 44 comparison samples were included 
in this study. This sized study should be interrupted with caution, as the margin of error 
is larger with a small population. It is also limited by not having the molecular 
diagnosis available on every sample that was tested. However, it would have been near 
impossible to select samples with molecular analysis available, particularly on the 
borderline CBA results. Another limitation is this study strictly analysed the CBA 
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levels and molecular analysis if it was available. This limits the ability to clinically 
correlate the diagnosis.  
Conclusions 
It was concluded, that even with a small sample size, that the AcuStarVWF:CB 
assay is a suitable replacement to the ELISA assay.  
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